Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Age-Related Macular Degeneration (AMD) treatment in Spain includes intravitreal injections of anti-VEGF agents like Lucentis or Eylea, and photodynamic therapy with Visudyne. These treatments aim to prevent progression of the disease and preserve central vision.
Spain's public healthcare system covers AMD treatment for residents, but waiting times can be long (up to 3 months). Private clinics offer faster access at additional cost.